What is Axol Bioscience?
Axol Bioscience specializes in the supply of human cell culture systems and custom services tailored for disease modeling and drug discovery. The company's offerings are crucial for researchers and pharmaceutical companies seeking to develop novel therapeutics and gain deeper insights into complex biological processes. By providing advanced cell culture technologies, Axol Bioscience aims to accelerate the pace of scientific breakthroughs and enhance the efficiency of drug development pipelines.
How much funding has Axol Bioscience raised?
Axol Bioscience has raised a total of $8.8M across 3 funding rounds:
Angel/Seed
$1.4M
Unspecified
$3.2M
Unspecified
$4.2M
Angel/Seed (2016): $1.4M, investors not publicly disclosed
Unspecified (2017): $3.2M led by Calculus Capital
Unspecified (2022): $4.2M supported by Scottish Enterprise, Calculus Capital, and Par Equity
Key Investors in Axol Bioscience
Scottish Enterprise
Scottish Enterprise is a national economic development agency focused on driving economic growth and innovation within Scotland, likely supporting companies with high growth potential in sectors like biotechnology.
Calculus Capital
Calculus Capital is an investment manager specializing in tax-efficient growth capital for UK smaller companies, with a focus on high-growth technology and healthcare businesses, indicating a strategic interest in Axol Bioscience's drug discovery applications.
Par Equity
Par Equity is an investment firm that supports innovative companies, suggesting a focus on Axol Bioscience's technological advancements in cell culture and its potential for market disruption in the life sciences sector.
What's next for Axol Bioscience?
The recent major strategic investment positions Axol Bioscience for accelerated expansion and innovation. This capital injection is expected to fuel further research and development into next-generation cell culture technologies, potentially broadening the company's product portfolio and market reach. Strategic partnerships and collaborations are likely to be a key focus, leveraging the expertise of its backers to enhance its capabilities in disease modeling and drug discovery. The company's trajectory suggests a strong emphasis on scaling its operations to meet the growing global demand for advanced biological research tools.
See full Axol Bioscience company page
